13F Holdings
中文EN

VXRT Vaxart, Inc.

Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 72444 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY22.3%
TTM net income YoY157.3%
TTM EPS YoY—
Revenue 3-yr CAGR252.0%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin16.6%
Net margin16.0%
FCF margin17.6%
EBITDA margin19.3%

Returns

ROE62.4%
ROA16.3%
ROIC (approx.)143.3%
Asset turnover1.02x

Leverage & solvency

Liabilities / assets55.3%
Debt / equity0.00x
Current ratio1.71x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.13x
Accruals ratio-2.1%
Payout ratio—
Capex / revenue0.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$237.26M$28.70M$7.38M$107,000$892,000
R&D expense$201.58M$74.21M$68.14M$81.05M$48.75M
SG&A expense$17.61M$20.78M$22.58M$29.39M$21.89M
Operating income$18.07M-$66.29M-$83.35M-$114.59M-$72.75M
Interest expense————$0
Pretax income$16.80M-$66.69M-$82.20M-$107.69M-$70.36M
Income tax$476,000$260,000$261,000$67,000$107,000
Net income$16.33M-$66.95M-$82.47M-$107.76M-$70.47M
EBITDA$26.65M-$57.44M-$74.72M-$108.78M-$68.54M
EPS (basic)0.07-0.33-0.57-0.84-0.58
EPS (diluted)0.07-0.33——-0.58
Weighted avg. shares (diluted)230.35M202.14M——121.45M
Balance sheet
Cash & equivalents$53.81M$25.23M$34.76M$46.01M$143.75M
Short-term investments$9.99M$26.49M$4.96M$49.70M$22.74M
Receivables$14.56M$5.76M$3.01M$20,000$71,000
Current assets$136.12M$68.26M$45.54M$99.45M$169.17M
PP&E, net$5.43M$8.71M$11.73M$15.59M$6.60M
Goodwill$4.51M$4.51M$4.51M$4.51M$4.51M
Intangibles$2.83M$3.56M$4.29M$5.02M$10.62M
Total assets$186.08M$166.39M$91.83M$153.85M$221.17M
Current liabilities$86.75M$90.88M$13.72M$17.92M$10.78M
Total liabilities$98.28M$107.46M$34.02M$43.25M$33.64M
Shareholders' equity$87.80M$58.92M$57.80M$110.60M$187.53M
Shares outstanding240.49M227.77M153.45M134.20M125.59M
Cash flow statement
Operating cash flow$7.71M-$44.76M-$70.45M-$94.78M-$59.83M
Capital expenditure$145,000$554,000$1.87M$9.60M$5.16M
Free cash flow$7.57M-$45.32M-$72.32M-$104.38M-$64.99M
Investing cash flow$16.63M-$21.32M$43.95M-$20.41M-$49.10M
Financing cash flow$4.24M$56.56M$15.24M$17.46M$125.80M
Depreciation & amortization$8.58M$8.85M$8.62M$5.80M$4.21M
Stock-based compensation$8.31M$11.50M$14.13M$13.59M$8.87M

Free plan shows the latest 5 periods; Pro shows all 19 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.